wpv01
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 3, 2022 (NCT06205329)
Timeline
Indications
Mechanism of action
- SARS-CoV-2INHIBITOR
SARS-CoV-2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07080658 | Phase 1 | Jul 23, 2023 | Government of China, Shandong Province Qianfoshan Hospital |
| NCT06197217 | Phase 3 | Jun 14, 2023 | Government of China |
| NCT05752175 | Phase 2 | Mar 10, 2023 | Government of China, Hangzhou Hospital of Traditional Chinese Medicine |
| NCT06205329 | Phase 1 | Oct 3, 2022 | Government of China |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 4 | 4 | 3 | 2022 |
| Hangzhou Hospital of Traditional Chinese Medicine | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shandong Province Qianfoshan Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1